AI Engines For more Details: Perplexity Kagi Labs You
Diuretic Effect: Canrenoic acid potassium salt works by increasing the excretion of sodium and water from the body while retaining potassium. This helps to reduce fluid buildup in the body, leading to decreased blood volume and lower blood pressure.
Hypertension Management: It may be prescribed to help lower blood pressure in individuals with hypertension, either alone or in combination with other antihypertensive medications.
Edema Treatment: Canrenoic acid potassium salt is commonly used to treat edema associated with conditions such as congestive heart failure, liver cirrhosis, and kidney disease by promoting the removal of excess fluid from the body.
Heart Failure Management: It may be used as part of the treatment for heart failure to reduce fluid overload and alleviate symptoms such as shortness of breath and swelling.
Potassium-Sparing Action: Similar to canrenone, canrenoic acid potassium salt helps to retain potassium in the body, which is important for maintaining normal heart rhythm and muscle function.
Reduction of Aldosterone Effects: Canrenoic acid potassium salt acts as an antagonist of aldosterone, a hormone that regulates sodium and potassium balance in the body. By blocking aldosterone's effects, it helps to reduce sodium and water retention.
Management of Ascites: Canrenoic acid potassium salt may be used to manage ascites, which is the accumulation of fluid in the abdominal cavity often seen in liver cirrhosis.
Prevention of Hypokalemia: Its potassium-sparing effect helps prevent hypokalemia (low potassium levels), which can occur with other diuretics that promote potassium excretion.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0 | 0 | |
Acne | 0.1 | -0.1 | |
ADHD | 2.3 | 0.1 | 22 |
Age-Related Macular Degeneration and Glaucoma | 0.3 | 0.1 | 2 |
Allergic Rhinitis (Hay Fever) | 1.2 | 0.3 | 3 |
Allergies | 2.1 | 0.4 | 4.25 |
Allergy to milk products | 1.4 | 0.6 | 1.33 |
Alopecia (Hair Loss) | 0.6 | 0.6 | |
Alzheimer's disease | 3 | 1.9 | 0.58 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.9 | 0.9 | 0 |
Ankylosing spondylitis | 2.4 | 0.9 | 1.67 |
Anorexia Nervosa | 0.1 | 1.1 | -10 |
Antiphospholipid syndrome (APS) | 2.2 | 0 | 0 |
Asthma | 0.6 | 0.5 | 0.2 |
Atherosclerosis | 0.6 | 0.4 | 0.5 |
Atrial fibrillation | 1.3 | 1 | 0.3 |
Autism | 3.4 | 2.8 | 0.21 |
Barrett esophagus cancer | 0.5 | 0.4 | 0.25 |
benign prostatic hyperplasia | 0.5 | 0.5 | |
Bipolar Disorder | 0.9 | 0.4 | 1.25 |
Brain Trauma | 0.1 | 0.5 | -4 |
Carcinoma | 1.9 | 0.9 | 1.11 |
Celiac Disease | 1.7 | 1 | 0.7 |
Cerebral Palsy | 0.7 | 0.9 | -0.29 |
Chronic Fatigue Syndrome | 3.1 | 2.2 | 0.41 |
Chronic Kidney Disease | 1.1 | 0.2 | 4.5 |
Chronic Lyme | 0.5 | -0.5 | |
Chronic Obstructive Pulmonary Disease (COPD) | 2.4 | 0.2 | 11 |
Chronic Urticaria (Hives) | 2 | 0.2 | 9 |
Coagulation / Micro clot triggering bacteria | 1.8 | 0.9 | 1 |
Colorectal Cancer | 4.3 | 0.1 | 42 |
Constipation | 0.9 | 0.5 | 0.8 |
Coronary artery disease | 0.1 | 0.4 | -3 |
COVID-19 | 7.3 | 6.4 | 0.14 |
Crohn's Disease | 5 | 1.8 | 1.78 |
cystic fibrosis | 1.4 | 0.6 | 1.33 |
deep vein thrombosis | 1.4 | 0.6 | 1.33 |
Depression | 6.1 | 2.4 | 1.54 |
Dermatomyositis | 0.4 | 0.1 | 3 |
Eczema | 0.6 | 1.5 | -1.5 |
Endometriosis | 2.6 | 0 | 0 |
Eosinophilic Esophagitis | 0.5 | 0 | 0 |
Epilepsy | 2.3 | 1.1 | 1.09 |
Fibromyalgia | 1.4 | 0.9 | 0.56 |
Functional constipation / chronic idiopathic constipation | 3.3 | 1.8 | 0.83 |
gallstone disease (gsd) | 1.2 | 0.8 | 0.5 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.8 | 1.1 | -0.38 |
Generalized anxiety disorder | 2.3 | 0.6 | 2.83 |
giant cell arteritis | 0.2 | -0.2 | |
Glioblastoma | 0.4 | -0.4 | |
Graves' disease | 0.5 | 0.6 | -0.2 |
Halitosis | 0.8 | 0.4 | 1 |
Hashimoto's thyroiditis | 1 | 0.4 | 1.5 |
Hidradenitis Suppurativa | 0.9 | 0 | 0 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.7 | 0.4 | 3.25 |
hypercholesterolemia (High Cholesterol) | 0.2 | 0 | 0 |
hyperglycemia | 0.5 | 0.9 | -0.8 |
Hyperlipidemia (High Blood Fats) | 0.1 | 0.1 | |
hypersomnia | 0.4 | -0.4 | |
hypertension (High Blood Pressure | 1.3 | 2.1 | -0.62 |
Hypothyroidism | 0.6 | -0.6 | |
Hypoxia | 0.4 | 0.4 | |
IgA nephropathy (IgAN) | 2.5 | -2.5 | |
Inflammatory Bowel Disease | 3.5 | 1.6 | 1.19 |
Insomnia | 1 | 0.5 | 1 |
Intelligence | 0.5 | 0.5 | |
Intracranial aneurysms | 0.8 | 0.8 | |
Irritable Bowel Syndrome | 3.8 | 2.1 | 0.81 |
Liver Cirrhosis | 2.7 | 1.3 | 1.08 |
Long COVID | 4.6 | 3.4 | 0.35 |
Low bone mineral density | 0.2 | -0.2 | |
Lung Cancer | 1.2 | 0.4 | 2 |
ME/CFS with IBS | 0.8 | 1.2 | -0.5 |
ME/CFS without IBS | 1.2 | 0.8 | 0.5 |
Menopause | 1.1 | 1.1 | |
Metabolic Syndrome | 4.8 | 3.5 | 0.37 |
Mood Disorders | 6.6 | 2.6 | 1.54 |
multiple chemical sensitivity [MCS] | 1 | 0.3 | 2.33 |
Multiple Sclerosis | 3.4 | 2 | 0.7 |
Multiple system atrophy (MSA) | 1.3 | 0.4 | 2.25 |
Neuropathy (all types) | 0.7 | 0.5 | 0.4 |
neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.5 | 1.6 | -0.07 |
NonCeliac Gluten Sensitivity | 0.1 | -0.1 | |
Obesity | 3.6 | 2.1 | 0.71 |
obsessive-compulsive disorder | 4.4 | 1 | 3.4 |
Osteoarthritis | 1.8 | 1.8 | |
Osteoporosis | 1.1 | 0.7 | 0.57 |
pancreatic cancer | 0.4 | 0.4 | |
Parkinson's Disease | 1.6 | 2.1 | -0.31 |
Polycystic ovary syndrome | 1.5 | 0.5 | 2 |
Postural orthostatic tachycardia syndrome | 0.2 | 0.1 | 1 |
Premenstrual dysphoric disorder | 0.4 | 0.1 | 3 |
primary biliary cholangitis | 0.1 | 0.3 | -2 |
Psoriasis | 2.3 | 0.8 | 1.87 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.2 | 1.6 | 1 |
Rosacea | 0.1 | 0.4 | -3 |
Schizophrenia | 1.9 | 0.8 | 1.37 |
scoliosis | 0 | 0 | |
Sjögren syndrome | 1.3 | 1.4 | -0.08 |
Sleep Apnea | 0.9 | 1 | -0.11 |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.7 | 1.7 | |
Stress / posttraumatic stress disorder | 2.4 | 0.9 | 1.67 |
Systemic Lupus Erythematosus | 2.6 | 0.6 | 3.33 |
Tic Disorder | 0.1 | 0.2 | -1 |
Tourette syndrome | 0 | 0.3 | 0 |
Type 1 Diabetes | 2.4 | 1.1 | 1.18 |
Type 2 Diabetes | 4.7 | 4.7 | 0 |
Ulcerative colitis | 2.8 | 2.3 | 0.22 |
Unhealthy Ageing | 2.9 | 0.3 | 8.67 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.